Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition

Leishmaniasis

(2018) Sakib Burza et al.   LANCET

Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis

(2018) Susan Wyllie et al.   NATURE

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

(2016) Shilpi Khare et al.   NATURE

The inhibition mechanism of human 20Sproteasomes enables next-generation inhibitor design

(2016) Jil Schrader et al.   SCIENCE

Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial

(2016) Monique Wasunna et al.   PLoS Neglected Tropical Diseases

Development and Validation of a Novel Leishmania donovani Screening Cascade for High-Throughput Screening Using a Novel Axenic Assay with High Predictivity of Leishmanicidal Intracellular Activity

(2015) Andrea Nühs et al.   PLoS Neglected Tropical Diseases

Failure of Miltefosine in Visceral Leishmaniasis Is Associated With Low Drug Exposure

(2014) T. P. C. Dorlo et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome® for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial

(2014) Eltahir A. G. Khalil et al.   PLoS Neglected Tropical Diseases

Epidemiology of visceral leishmaniasis

(2014) Paul Ready   Clinical Epidemiology

Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay

(2013) Manu De Rycker et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance

(2013) Suman Rijal et al.   CLINICAL INFECTIOUS DISEASES

Drug Discovery for Neglected Diseases: Molecular Target-Based and Phenotypic Approaches

(2013) Ian H. Gilbert   JOURNAL OF MEDICINAL CHEMISTRY

Screening strategies to identify new chemical diversity for drug development to treat kinetoplastid infections

(2013) ROB DON et al.   PARASITOLOGY

Probing the Specificity and Activity Profiles of the Proteasome Inhibitors Bortezomib and Delanzomib

(2012) Celia R. Berkers et al.   MOLECULAR PHARMACEUTICS

High-throughput decoding of antitrypanosomal drug efficacy and resistance

(2012) Sam Alsford et al.   NATURE

Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells

(2009) K Zhu et al.   ONCOGENE